Aron R. English Sells 12,334 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) Stock

Lifecore Biomedical, Inc. (NASDAQ:LFCR) major shareholder Aron R. English sold 12,334 shares of the stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $7.00, for a total transaction of $86,338.00. Following the completion of the sale, the insider now directly owns 1,650,240 shares in the company, valued at approximately $11,551,680. This represents a 0.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Lifecore Biomedical Trading Up 2.7%

Shares of NASDAQ:LFCR opened at $6.89 on Monday. Lifecore Biomedical, Inc. has a 52 week low of $3.68 and a 52 week high of $7.99. The company’s 50 day moving average is $6.48 and its two-hundred day moving average is $6.55. The company has a current ratio of 2.32, a quick ratio of 1.21 and a debt-to-equity ratio of 9.21. The company has a market cap of $255.10 million, a PE ratio of -12.30 and a beta of 0.65.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings data on Thursday, April 3rd. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. The firm had revenue of $35.15 million during the quarter, compared to analysts’ expectations of $33.23 million. Equities analysts predict that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lifecore Biomedical

A number of large investors have recently modified their holdings of LFCR. Barclays PLC boosted its holdings in shares of Lifecore Biomedical by 301.7% in the 3rd quarter. Barclays PLC now owns 29,944 shares of the company’s stock valued at $147,000 after buying an additional 22,489 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its holdings in shares of Lifecore Biomedical by 61.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 27,184 shares of the company’s stock valued at $202,000 after buying an additional 10,320 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Lifecore Biomedical by 71.9% in the 4th quarter. Bank of New York Mellon Corp now owns 80,572 shares of the company’s stock valued at $599,000 after buying an additional 33,690 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Lifecore Biomedical by 125.9% in the 4th quarter. Rhumbline Advisers now owns 55,723 shares of the company’s stock valued at $414,000 after buying an additional 31,056 shares in the last quarter. Finally, Rangeley Capital LLC acquired a new position in shares of Lifecore Biomedical in the 4th quarter valued at $325,000. 83.36% of the stock is owned by hedge funds and other institutional investors.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.